Global Prostate Cancer Market Industry Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

The global prostate cancer market includes pharmaceuticals, hormone therapies, precision oncology agents, and supportive treatments designed to address disease progression across early-stage, advanced, and metastatic settings. Market estimates for 2025 range from approximately $12.9 billion to $20.4 billion depending on whether analysts focus on therapeutics alone or include broader treatment categories, with the broader treatment market converging around $16 billion. Government health agencies track disease incidence and patient prevalence rather than commercial market valuations, leaving private research firms to calculate addressable market sizes using treatment pricing, patient volumes, and adoption rates.

• •Therapeutics segment valued at roughly $13.5 billion in 2024, projected to reach $21.2 billion by 2030
• •Precision oncology for prostate cancer valued at $12.16 billion in 2024, forecast at $20.95 billion by 2030
• •Castrate-resistant prostate cancer segment valued at $12.9 billion in 2024, forecast at $21.4 billion by 2030

Rising global incidence of prostate cancer, particularly in aging male populations across North America, Europe, and increasingly in Asia-Pacific, is a fundamental driver of market expansion. The introduction of novel targeted therapies, including androgen receptor inhibitors and radiopharmaceuticals, along with immunotherapies and PARP inhibitors, has significantly improved treatment options for advanced disease. Growing adoption of precision medicine approaches, including biomarker-driven treatment selection and companion diagnostics, is extending both the duration and value of treatment regimens.

• •Hormone therapy segment projected to reach $83.1 billion by 2034 at a 14.67% CAGR
• •Precision oncology segment growing at 9.5% CAGR through 2030
• •Combined market projections across major research firms converge on $28-34 billion by 2034-2035

The market is segmented by therapy type, including hormone therapy, chemotherapy, targeted therapy, immunotherapy, and radiation-based treatments, with hormone therapy remaining the dominant category. Geographically, North America holds the largest market share due to high prevalence, advanced healthcare infrastructure, and early adoption of novel therapies, followed by Europe with strong regulatory frameworks and growing Asia-Pacific markets driven by rising awareness and improving access. The castrate-resistant and metastatic segments represent particularly high-value submarkets as patients progress through treatment lines.

• •Hormone therapy accounts for the largest single segment, estimated at $20.44 billion in 2025
• •North America leads in market share, with Europe and Asia-Pacific as key growth regions
• •Advanced and metastatic disease segments command premium pricing and strong pipeline activity

What are the recent trends and outlook?

The market is moving toward personalized treatment approaches, with increasing reliance on biomarker testing, genomic profiling, and companion diagnostics to match therapies with individual patient characteristics. Combination regimens pairing hormone therapies with immunotherapies, targeted agents, or radiopharmaceuticals are showing promise in clinical trials and are expected to shape future standard-of-care protocols. Radiopharmaceuticals and next-generation androgen receptor degraders represent particularly active areas of pipeline development that could further expand the market through the 2030s.

• •Radiopharmaceuticals emerging as a transformative category with growing adoption of PSMA-targeted therapies
• •Combination therapy strategies gaining momentum in clinical development programs
• •Overall market projected to nearly double over the next decade across most research estimates